What were the key takeaways from Iovance’s earnings call?

What is the market's earnings forecast for Iovance next quarter?

What guidance did Iovance's management provide for the next earnings period?

What is the revenue and EPS growth rate for Iovance year over year?

What is Iovance's latest dividend and current dividend yield?

What were the key takeaways from Iovance's earnings call?

What is Iovance's gross profit margin?

Did Iovance beat or miss consensus estimates last quarter?

- **Revenue Growth**: 30% YoY to $264 million, driven by Amtagvi with 50% Q4 gross margin.
- **Strategic Expansion**: FDA fast-track for NSCLC and 50% ORR in sarcomas, targeting $1 billion+ melanoma sales.
- **Operational Strength**: Internalized manufacturing at ICTC extends cash runway to Q3 2027.
- **Pipeline Momentum**: Single-arm sarcoma trial and NSCLC BLA in 2027, with next-gen IL-2 therapies in development.
- **Community Growth**: Community ATCs expected to double in 2026, supporting Amtagvi's $1 billion+ potential.

**【CEO Summary Section】**
- **2025 Performance Overview**: Achieved 30% revenue growth to $264 million, driven by Amtagvi adoption. Gross margin reached 50% in Q4, with cash runway extended to Q3 2027.
- **Three Strategic Pillars**: 
  1. Accelerate U.S. launch of Amtagvi in melanoma, targeting $1 billion+ peak sales.
  2. Expand TIL pipeline into NSCLC (7x larger market) and sarcomas (50% ORR in pilot trial).
  3. Operational excellence, including internalized manufacturing at ICTC and cost optimization.
- **Regulatory Milestones**: FDA fast-track for lifileucel in NSCLC and 50% ORR in sarcomas, positioning for 2027 launches.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Product revenue $87 million (30% QoQ growth), total revenue $264 million (61% YoY growth). Gross margin improved to 50% from 43% Q3.
- **Financial Health**: Cash position $303 million, with minimal gross-to-net adjustments (2% of revenue). Proleukin sales driven by Amtagvi demand, stabilizing at 17% of total revenue.
- **Operational Efficiency**: Internalized manufacturing reduces costs, supporting scalability without capital expenses.

**【CFO Manufacturing Update】**
- **Manufacturing Success**: Q4 marked highest volume and success rates, with ICTC now modular for uninterrupted supply. Annual maintenance minimized impact via contract manufacturing.

**【CMO and Pipeline Updates】**
- **Lifileucel Progress**: Fast-track designation for NSCLC, with Phase III trial on track for 2027 BLA. Sarcoma trial shows 50% ORR, targeting single-arm registrational study.
- **Pipeline Expansion**: Exploring additional sarcoma subtypes and next-gen IL-2 therapies for broader solid tumor impact.

**【Q&A Highlights】**
- **Guidance Timing**: 2026 revenue guidance pending, with focus on Amtagvi growth and NSCLC launch.
- **Community ATC Expansion**: Community centers expected to double in 2026, complementing academic ATCs.
- **Sarcoma Data Depth**: Responses deepening over time, with durability comparable to melanoma trials.
- **Ex-U.S. Impact**: No margin dilution from ex-U.S. launches, leveraging existing manufacturing scale.
- **Manufacturing Scrap Costs**: Consistent with prior quarters, improving via internal and commercial initiatives.

Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: Q3 revenue of $68 million (+13% QoQ) driven by Amtagvi ($58M) and Proleukin ($10M), with 2025 guidance reaffirmed at $250-300 million.
- **Lung Cancer Breakthrough**: Lifileucel interim data shows 26% ORR and unprecedented DoR in NSCLC, targeting 2027 U.S. launch with $10B peak sales potential.
- **Gross Margin Expansion**: 43% Q3 gross margin (vs. prior quarter) from cost optimization and restructuring, with full internal manufacturing to drive further improvements.
- **Pipeline Momentum**: LUN-202 trial on track for 80-patient enrollment in 2026, with global expansion plans for Amtagvi in 2027.
- **Financial Strength**: $307M cash position supports operations into Q2 2027, with 10% sequential expense reduction excluding restructuring.

**【Management Opening Remarks】**
- Interim CEO Fred Vogt highlighted Q3 revenue growth of 13% over the prior quarter, driven by Amtagvi sales of $58 million and Proleukin revenue of $10 million.
- Gross margin improved to 43% due to restructuring and cost optimization, with further improvements expected from transitioning manufacturing to the internal iCTC facility in early 2026.
- The company reaffirmed full-year 2025 revenue guidance of $250-300 million and projected Amtagvi peak U.S. sales exceeding $1 billion.

**【CEO Commentary】**
- Interim CEO Fred Vogt emphasized the potential of Lifileucel in non-squamous non-small cell lung cancer (NSCLC), citing interim data showing a 26% objective response rate (ORR) and median duration of response (DoR) not reached at 25+ months.
- The LUN-202 registrational trial is on track to complete enrollment of 80 patients in 2026, with plans for a supplemental BLA submission in 2027.
- The NSCLC market opportunity is 7x larger than advanced melanoma, with potential U.S. peak sales of $10 billion.

**【CFO Financial Commentary】**
- Q3 total product revenue reached $68 million, up 13% sequentially, with Amtagvi and Proleukin sales growing 13% and 50%, respectively.
- Cost of sales decreased 21% YoY, driving gross margin improvement to 43%.
- Cash position of $307 million as of Q3 end supports operations into Q2 2027.
- Expense reduction initiatives achieved a 10% sequential decline in total costs, excluding restructuring charges.

**【Q&A Highlights】**
- **Lung Cancer Trial Enrollment**: CMO Friedrich Finckenstein reported double-digit patients awaiting infusion in LUN-202, with enrollment accelerating due to positive data reception.
- **Manufacturing Transition**: COO Igor Bilinsky confirmed all Amtagvi and clinical manufacturing will shift to iCTC in early 2026, enabling uninterrupted supply and cost savings.
- **Revenue Guidance**: CEO Vogt reiterated confidence in achieving $250-300 million 2025 guidance, citing strong Q4 demand and Proleukin sales growth.
- **Global Expansion**: CCO Dan Kirby noted Canada as the first new market for Amtagvi, with U.K., Australia, and Switzerland approvals pending, targeting 2027 ex-U.S. revenue contribution.
- **Gross Margin Drivers**: CFO Corleen Roche attributed margin improvement to 40% reduction in patient drop-off costs and restructuring benefits, with further gains expected from internal manufacturing.


Iovance Biotherapeutics, Inc. (IOVA) Q3 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: Q2 Amtagvi infusions hit 102 patients (24% QoQ), driving $54M in revenue.
- **Cost Savings Materialize**: $100M+ annual savings from 19% workforce reduction, improving gross margin to 31%.
- **Manufacturing Efficiency**: Turnaround time reduced to 33 days, with success rates improving 20%+ in Q2.
- **Pipeline Momentum**: NSCLC registrational trial on track for 2027 approval; next-gen TIL therapy enters Phase I.
- **International Expansion**: Canada approval imminent; specialty pharmacy channel expands U.S. community access.

**【Interim CEO & President Remarks】**
- Q2 2025 total revenue: $60 million (22% QoQ growth), including $54M from Amtagvi and $6M from Proleukin.
- Full-year 2025 revenue guidance reaffirmed: $250-300 million, driven by U.S. Amtagvi adoption and Proleukin restocking.
- Strategic restructuring announced: 19% workforce reduction to achieve >$100M annual cost savings starting Q4 2025.
- Gross margin (non-GAAP): 31%, with near-term improvements from reduced cost of sales and manufacturing optimization.
- Cash runway extended to Q4 2026 with $307M current balance and projected net cash burn <$245M over next 4 quarters.

**【Chief Commercial Officer Update】**
- Amtagvi infusions reached 102 patients in Q2 (vs. 83 in Q1), with 24% QoQ growth.
- ProleukinQ, with 2/3 U revenue increased 2% Qo.S. wholesalers reordering in main channel.
- New specialty pharmacy channel with McKesson to expand access for community oncology practices.
- International regulatory progress: Canada approval imminent, U.K. and Australia submissions under review.

**【Chief Operating Officer Update】**
- Manufacturing turnaround time reduced to 33 days, with success rates improving in Q2.
- Internal manufacturing facility (iCTC) now supplies >90% of Amtagvi demand, enabling cost control.
- Restructuring reduced manufacturing headcount by 20%, aligning capacity with revised growth projections.

** data: 4【Chief Medical Officer Update】**
- Amtagvi real-world9% response rate (n=41), 61% in ≤3rd-line settings.
- Phase III trial (TILVANCE-301) in frontline melanoma remains on track for potential 2026 readout.
- Registrational trial for NSCLC (IOV-LUN-202) expected to support 2027 accelerated approval.
- Next-gen PD-1 inactivated TIL therapy (IOV-4001) in Phase I/II clinical trial.

**【Q&A Highlights】**
- Patient drop-off rates and out-of-spec manufacturing rates improved in Q2, with further gains expected in Q3.
- European EMA withdrawal due to request for additional virtual control arm analysis; resubmission planned with scientific advice.
- No material impact on R&D expenses; clinical trials remain on track despite workforce reduction.
- Specialty pharmacy channel could add 10-20 new ATCs in 2025, targeting earlier-stage melanoma patients.

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue $49.3M, with full-year guidance $250-300M driven by ATC expansion and manufacturing recovery.
- **Manufacturing Recovery**: Q2 production starts at record levels, targeting 100-110 infusions after Q1 capacity constraints.
- **Gross Margin Target**: >70% achievable through scale, with Q1 gross margin at 10% due to patient drop-offs.
- **Global Expansion**: 15 international ATCs expected by year-end, with EU, UK, and Canada approvals anticipated.
- **Pipeline Momentum**: Lung cancer data expected H2 2025, and next-gen therapies like IOV-5001 advancing into clinical trials.


**【CEO Summary Section】**
- **Revenue Performance**: Total Q1 2025 product revenue was $49.3 million, including $43.6 million from 80 Amtagvi infusions and $5.7 million from Proleukin sales. Full-year 2025 revenue guidance revised to $250-300 million, driven by ATC adoption and manufacturing alignment.
- **Manufacturing Challenges**: Q1 capacity reduced by 50% due to ICTC maintenance, impacting infusions. Q2 production starts are at record levels, with 100-110 infusions projected.
- **Gross Margin Outlook**: Targeting >70% gross margin in coming years through scale and efficiency improvements.
- **Global Expansion**: Anticipating approvals in UK, Canada, and EU, with 15 international ATCs expected by year-end.

**【CCO Commercial Update】**
- **ATC Network**: 70 active ATCs, with 11 centers completing >10 infusions. 10 new international ATCs in process for ex-US launches.
- ** Physician Engagement**: Revamping medical oncologist education to shift Amtagvi from 3rd-line to 2nd-line treatment in melanoma.
- **Community Oncology Expansion**: Collaborating with top U.S. community networks to identify preferred centers and reduce patient delays.
- **Proleukin Strategy**: Replenishing distributor inventory and growing clinical/research sales to offset Q1 declines.

**【COO Manufacturing Update】**
- **Capacity & Compliance**: ICTC and contract manufacturer passed EMA GMP inspections for EU launch. Q1 manufacturing success rate rebounded post-maintenance.
- **Cost Optimization**: Shortening turnaround time from 34 days to <30 days, aligning capacity with demand forecasts.
- **Tariff Resilience**: <5% of Amtagvi COGS from ex-US vendors; U.S.-based IP and manufacturing minimize trade risks.

**【CFO Financial Review】**
- **Q1 Financials**: Net loss $116.2M; cash position $366M. Gross margin 10% (vs. 32% standard), impacted by patient drop-offs and lower success rates.
- **Expense Management**: 2025 cash burn <$300M, with focus on optimizing R&D and SG&A. Manufacturing cost alignment with demand to reduce COGS.
- **Long-Term Outlook**: Peak U.S. sales >$1B, global >$2B. Gross margin >70% achievable with scale.

**【CMO Pipeline Update】**
- **Lung Cancer Data**: IOV-LUN-202 trial results expected H2 2025, targeting accelerated approval in post-PD-1 NSCLC.
- **Frontline Melanoma**: TILVANCE-301 Phase 3 trial progressing for Amtagvi + pembrolizumab in frontline melanoma.
- **Next-Gen Therapies**: IOV-5001 IND submission planned for engineered IL-12 TILs; IOV-3001 Phase 1/2 trial ongoing for modified IL-2.

**【Q&A Highlights】**
- **Q2 Infusion Momentum**: 100-110 infusions projected, driven by new ATC activations and improved patient referrals.
- **Manufacturing Success Rate**: Q1 out-of-spec rate transient, rebounded in Q2 due to ATC best practices.
- **Proleukin Recovery**: Two major distributors expected to replenish inventory in Q2, supporting H2 growth.
- **Tariff Impact**: Minimal effect on U.S.-based manufacturing and supply chain.


Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript

- **Revenue milestone achieved**: Full year 2024 revenue of $164.1 million met upper guidance, driven by Amtagvi's 200+ patient treatments.
- **2025 growth target**: $450-475 million revenue outlook, supported by 70+ ATCs and global Proleukin expansion.
- **Gross margin improvement**: Q4 2024 at 46%, on track for >70% long-term target.
- **Ex-U.S. expansion**: 3 potential approvals in 2025 and 15 international treatment centers planned.
- **Competitive differentiation**: Amtagvi's focus on later-stage melanoma patients positions it above incoming T-VEC competitor.

**【CEO Summary Section】**
- Total product revenue for Q4 2024 was $73.7 million, with $48.7 million from Amtagvi and $25.0 million from Proleukin. Full year 2024 revenue reached $164.1 million, meeting the upper end of guidance.
- 2025 revenue guidance remains $450-475 million, driven by ATC expansion and global Proleukin sales growth.
- Gross margin improved to 46% in Q4 2024, with a long-term target of >70%.
- U.S. launch achieved 70 ATCs by end-2024, with 200+ patients treated in the first year.
- Ex-U.S. expansion plans include 3 potential approvals in 2025 and 15 international treatment centers.

**【CFO Financial Commentary】**
- Net loss for Q4 2024 was $78.6 million, with cash position of $330.1 million as of December 31, 2024.
- Cost of sales for Q4 2024 was $45.5 million, reflecting $9.1 million in patient drop-off and manufacturing costs.
- 2025 cash burn guidance is < $300 million, excluding one-time expenses.
- Proleukin sales grew due to restocking with 3 U.S. wholesalers, contributing $25.0 million in Q4.

**【Q&A Key Highlights】**
- Amtagvi infusions in Q4 2024: 95 revenue-generating cases, with 13% of ATCs treating >10 patients.
- No material seasonality observed in Q4 2024 demand.
- Competitor T-VEC launch expected in 2025, but Iovance views Amtagvi as superior due to later-stage patient focus.
- LUN-202 (non-small cell lung cancer) trial on track for 2027 FDA decision, with 26% response rate in prior data.
- Endometrial cancer trial (END-201) expected to report initial data in H2 2025.

Actual											-0.55	-0.47	-0.4	-0.47	-0.51	-0.53	-0.55	-0.63	-0.58	-0.63	-0.63	-0.64	-0.5	-0.47	-0.46	-0.45	-0.42	-0.34	-0.28	-0.26	-0.36	-0.33	-0.25	-0.18
Forecast											-0.5173	-0.5258	-0.4608	-0.4425	-0.4864	-0.5124	-0.5289	-0.5581	-0.6368	-0.6064	-0.638	-0.6371	-0.567	-0.4982	-0.4546	-0.4308	-0.4243	-0.3535	-0.2989	-0.2677	-0.2417	-0.2828	-0.2577	-0.1749
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.32%	+10.61%	+13.19%	-6.21%	-4.85%	-3.43%	-3.99%	-12.88%	+8.92%	-3.89%	+1.25%	-0.46%	+11.82%	+5.66%	-1.19%	-4.46%	+1.01%	+3.82%	+6.32%	+2.88%	-48.94%	-16.69%	+2.99%	-2.92%

Actual	--	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	238.00K	469.00K	482.00K	715.00K	31.11M	58.55M	73.69M	49.32M	59.95M	67.45M	86.71M
Forecast	--	--	--	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	222.22K	3.91M	4.50M	1.44M	2.03M	24.59M	53.79M	72.11M	82.37M	67.10M	72.85M	80.71M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-93.91%	-89.58%	-66.55%	-64.76%	+26.47%	+8.87%	+2.19%	-40.12%	-10.66%	-7.40%	+7.44%

IOVA

IOVA fundamentals

IOVA Q4 2025 Earnings

Earnings Call

You can ask Aime

IOVA

IOVA fundamentals

IOVA Q4 2025 Earnings

Earnings Call

IOVA Earnings Call Summary for Q4/20258:30 AM on Feb 24, 2026

IOVA Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

IOVA Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

IOVA Earnings Call Summary for Q1/20254:30 PM on May 8, 2025

IOVA Earnings Call Summary for Q4/20244:30 PM on Feb 27, 2025

You can ask Aime